PCR Tests

Global PCR Tests Market to Reach US$32.5 Billion by 2030

The global market for PCR Tests estimated at US$23.8 Billion in the year 2024, is expected to reach US$32.5 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Standard PCR Test, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.8 Billion by the end of the analysis period. Growth in the Real-Time PCR Test segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.5 Billion While China is Forecast to Grow at 8.8% CAGR

The PCR Tests market in the U.S. is estimated at US$6.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global PCR Tests Market - Key Trends & Drivers Summarized

Why Are PCR Tests Still the Gold Standard in Molecular Diagnostics?

Polymerase Chain Reaction (PCR) testing continues to stand at the forefront of molecular diagnostics due to its high specificity, sensitivity, and versatility in detecting nucleic acids across a broad spectrum of pathogens, genetic conditions, and oncology biomarkers. While initially introduced as a tool for basic research, PCR has become central to clinical diagnostics, food safety testing, forensic analysis, and environmental monitoring. Its application surged globally during the COVID-19 pandemic, and its relevance continues to evolve across routine diagnostics and precision medicine.

In infectious disease diagnostics, PCR remains the gold standard for confirming active infections, with real-time quantitative PCR (qPCR) and multiplex PCR systems offering rapid turnaround and the ability to detect multiple targets simultaneously. These capabilities are essential for managing respiratory infections (e.g., influenza, RSV, SARS-CoV-2), sexually transmitted infections, and tropical diseases such as dengue and Zika. PCR also plays a crucial role in hospital-acquired infection control by enabling early detection of drug-resistant strains like MRSA or C. difficile.

Outside infectious disease, PCR is integral in genetic and prenatal screening, detecting single-nucleotide polymorphisms (SNPs), gene fusions, and chromosomal abnormalities. Oncology diagnostics increasingly rely on PCR-based assays to identify actionable mutations in tumors, guide targeted therapies, and monitor minimal residual disease. In non-clinical domains, PCR is used in water testing, agricultural pathogen detection, and food contamination screening, emphasizing its cross-industry utility and standardization.

What Technological Advancements Are Reshaping PCR Testing Platforms?

The evolution of PCR technologies has been shaped by a need for higher throughput, faster cycling times, greater multiplexing capability, and improved point-of-care (POC) applicability. Traditional thermal cyclers are being replaced or supplemented by integrated systems combining sample preparation, amplification, and detection in a single closed unit. This reduces contamination risks and simplifies workflow, particularly in resource-limited or field-based settings.

Digital PCR (dPCR) represents one of the most significant advances in the last decade. By partitioning the PCR reaction into thousands of nanoliter-scale reactions, dPCR enables absolute quantification of nucleic acids without the need for standard curves. This technology is gaining traction in oncology for liquid biopsy applications and in viral load monitoring, offering higher precision in low-abundance targets. Microfluidic-based PCR devices, including lab-on-a-chip platforms, are also enabling miniaturization and ultra-fast processing, crucial for emergency diagnostics and mobile health applications.

Multiplex PCR technologies are being refined to handle increasing numbers of targets in a single reaction, driven by the rise in syndromic panel testing. This is especially valuable for diagnosing respiratory or gastrointestinal diseases where symptoms overlap. AI-integrated PCR platforms are emerging that can interpret complex amplification data, suggest probable diagnoses, and feed into centralized databases for outbreak surveillance or patient record integration. These smart systems are expected to redefine how diagnostic data is collected, processed, and utilized.

Which End-Use Segments and Global Regions Are Fueling PCR Market Expansion?

Hospitals, diagnostic reference laboratories, academic research centers, biotechnology firms, and public health agencies are the core end-users of PCR test technologies. Hospital-based molecular labs are focusing on automating high-throughput PCR workflows to reduce test backlogs and support rapid clinical decision-making. Reference labs process large test volumes across multiple disease domains, often using multiplex and dPCR platforms to expand test menus and support contract research.

Research institutions use PCR to validate gene editing experiments, profile gene expression, and perform microbial sequencing. Biopharma firms depend on PCR-based assays for product safety testing, contamination control, and pharmacogenomic screening in clinical trials. Regulatory bodies and food safety authorities utilize PCR to track genetically modified organisms (GMOs), toxins, or banned substances across global supply chains, ensuring compliance with public health standards.

Geographically, North America leads in adoption due to well-established lab infrastructure, insurance reimbursement for molecular tests, and ongoing innovation from U.S.-based biotech companies. Europe is a close second, supported by coordinated public health screening programs and EU-based diagnostic manufacturers. Asia-Pacific is witnessing rapid growth, especially in China, India, and Southeast Asia, where infectious disease burden, public health investment, and rising molecular lab capacity drive demand. Latin America and Africa, while still emerging markets, are experiencing increased PCR deployment through global health funding initiatives and pandemic preparedness programs.

What Factors Are Propelling Growth in the Global PCR Tests Market?

The growth in the global PCR tests market is driven by the persistent need for early and accurate diagnosis, increasing infectious disease burden, expanding applications in oncology and genetic testing, and continual advancements in PCR automation, miniaturization, and multiplexing. As healthcare shifts toward precision medicine, the demand for nucleic acid-based testing is rising across both clinical and non-clinical settings.

Ongoing threats of viral outbreaks, antimicrobial resistance, and zoonotic diseases are fueling investments in real-time PCR platforms capable of rapid, multiplexed pathogen detection. Government initiatives to strengthen diagnostic capacity, along with funding from WHO, CDC, and Gates Foundation, are enabling broader PCR test availability, particularly in underserved regions. Emerging uses of PCR in decentralized testing, such as at-home molecular kits and POC devices, are expanding the market beyond institutional labs.

Moreover, PCR’s expanding role in companion diagnostics, transplant monitoring, prenatal screening, and personalized therapy monitoring ensures long-term market relevance. The regulatory landscape is also maturing, with increased pathways for test kit approvals, emergency use authorizations, and quality control standards. With molecular biology continuing to underpin modern medicine, PCR technologies remain indispensable, flexible, and highly scalable tools poised for enduring growth.

SCOPE OF STUDY:

The report analyzes the PCR Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Test Type (Standard PCR Test, Real-Time PCR Test, Digital PCR Test, Other Test Types); Product Type (Instruments, Reagents & Consumables, Software & Services); Indication (Infectious Diseases, Oncology, Genetic Disorders, Other Indications); End-Use (Hospitals & Clinics End-Use, Pharma & Biotech Industries End-Use, Diagnostics Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Abbott Laboratories
• Agilent Technologies
• Becton, Dickinson & Co. (BD)
• BGI Genomics
• Bio-Rad Laboratories
• Cepheid (Danaher)
• DiaSorin S.p.A.
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• Fujirebio
• GenMark Diagnostics
• Hologic
• Illumina Inc.
• LabCorp
• Luminex Corporation
• Meridian Bioscience
• Myriad Genetics
• Oxford Nanopore Technologies
• PerkinElmer
• Qiagen N.V.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more